Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 April, 2018 22:26 IST
Aurobindo Pharma gets USFDA nod for anti-cough tablets
Source: IRIS | 21 Mar, 2017, 09.14AM
Comments  |  Post Comment

Aurobindo Pharma announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets, 600/30 mg and 1200/60mg (OTC). Aurobindo's Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets are the AB rated generic equivalent of Reckitt Benckiser's Mucinex DM tablets. The product will be launched in Q1FY18.

Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets helps loosen mucus and phlegm, and thin out bronchial secretions, making coughs more productive. The approved product has an estimated market size of US$ 235 million for the twelve months ending December 2016 according to IRI database.

This is the 106 th ANDA (including 21 tentative approvals) approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 311 ANDA approvals (272 Final approvals including 16 from Aurolife Pharma LLC and 39 tentative approvals) from USFDA.

Shares of the company gained Rs 1.7, or 0.24%, to trade at Rs 704.90. The total volume of shares traded was 0 at the BSE (9.01 a.m., Tuesday).



Aurobindo Pharma Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Prism Cement is now Prism Johnson - 19-Apr-2018 15:51
NACL Ind enters into strategic alliance with BioWorks - 19-Apr-2018 15:25
Ramco Systems partners with L3 MAS - 19-Apr-2018 15:21
MCX inks pact with Northern India Textiles Mills' Association - 19-Apr-2018 15:16
BP and Reliance sanction second phase of integrated KG D6 development - 19-Apr-2018 13:45
IndusInd Bank Q4 profit grows 27% to Rs 9.53 bn - 19-Apr-2018 13:40
Reliance Infra wins EPC contract worth Rs 7.74 bn - 19-Apr-2018 12:07
WABAG secures Rs 2.53 bn order under Namami Gange scheme - 19-Apr-2018 11:39
UltraTech Cement commissions new plant in Madhya Pradesh - 19-Apr-2018 11:33
Vascon Engineers receives work order worth Rs 1.19 bn - 19-Apr-2018 11:27
Magma Fincorp raises Rs 5 bn through QIP route - 19-Apr-2018 10:15
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer